Accessibility Menu
Adicet Bio logo

Adicet Bio

(NASDAQ) ACET

Current Price$8.03
Market Cap$75.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-97%
5 Year-93%
1 Year-36%
1 Month+0%
Adicet Bio last closing stock price
MetricPriceDate
Last closeUSD 8.122026-07-17
Adicet Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.04%USD 8.832026-07-10
1 month+0.25%USD 8.102026-06-17
3 month-1.22%USD 8.222026-04-17
Year to date-3.56%USD 8.422025-12-31
1 year-35.76%USD 12.642025-07-17
3 year-83.84%USD 50.242023-07-18
5 year-93.49%USD 124.802021-07-16
Since inception-96.7%USD 246.402020-09-16

Adicet Bio Financials at a Glance

Market Cap

$75.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$108.83M

EPS (TTM)

-$15.03

P/E Ratio

-0.54

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$8.03

Volume

783

Open

$8.00

Previous Close

$8.12

Daily Range

$7.81 - $8.03

52-Week Range

$6.01 - $17.44

Estimated Earnings Date

Aug 6, 2026

ACET News

Foolcom-Featured.png

Adicet Bio (ACET) Q2 Loss Widens 3%

Motley Fool Markets TeamAug 7, 2025
Scientists in a lab, monitor, microscope

3 Biotech Stocks That Could Make You Richer in February (and Beyond)

Keith SpeightsFeb 5, 2022
Test tubes with green arrow pointing up

3 Biotech Stocks That Could Double in 2022

Keith SpeightsJan 3, 2022
Scientists working in a lab

Why Adicet Bio Stock Is Skyrocketing Today

Keith SpeightsDec 6, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adicet Bio

Adicet Bio, Inc. is a biotechnology company focusing on innovative cancer treatments. The company's main emphasis is on developing therapies using allogeneic gamma delta T cell technology, a promising strategy in the field of cancer immunotherapy.

Products and Services

Allogeneic gamma delta T cell therapy platform for cancer treatment.

Pipeline targeting both hematological malignancies and solid tumors.

What Makes Adicet Bio, Inc. Special

Adicet Bio, Inc. distinguishes itself through its use of gamma delta T cells, which naturally attack tumors without needing patient-specific modifications. This approach offers potential advantages in manufacturing scalability and broader patient applicability compared to traditional autologous CAR-T therapies.

Five Things You Need to Know

Adicet Bio's platform leverages the unique biology of gamma delta T cells for cancer treatment.

The company is expanding its therapeutic pipeline to target a wide range of cancers, including hematological malignancies and solid tumors.

Adicet possesses a strong leadership team with expertise in biopharmaceutical development and commercialization.

The company's approach potentially offers benefits over individualized CAR-T treatments, like scalability and wider patient reach.

Adicet Bio aims to address significant unmet medical needs, offering diverse revenue potential in the competitive immunotherapy market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

102

CEO

Chen Schor, MBA, CPA

Website

www.adicetbio.com

Headquarters

Boston, MA 02116, US

ACET Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-80.35%

Return on Capital

-70.20%

Return on Assets

-64.25%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$75.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.35M

Volume

783

Avg. Volume

96.63K

Financials (TTM)

Gross Profit

-$1.34M

Operating Income

-$113.80M

EBITDA

-$102.73M

Operating Cash Flow

-$91.34M

Capital Expenditure

-$283.00K

Free Cash Flow

-$91.62M

Cash & ST Invst.

$137.59M

Total Debt

$13.90M

Adicet Bio Performance Analysis

Adicet Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 24,990,000156.8%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Adicet Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Adicet Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -27.18-15.2%
20232023-12-31USD -53.0395.1%
20242024-12-31USD -21.33-59.8%
20252025-12-31USD -16.95-20.5%
Adicet Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-9.7%
Q32025-09-3014.7%
Q42025-12-3136.6%
Q12026-03-3136.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.34M

N/A

Gross Margin

0.00%

N/A

Market Cap

$75.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$744.19K

N/A

Employees

102

N/A

Net Income

-$20.24M

+28.2%

EBITDA

-$18.88M

+28.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$137.59M

-8.5%

Total Debt

$13.90M

-14.4%

Accounts Receivable

$405.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$11.02M

-16.9%

Short Term Debt

$2.88M

-3.5%

Return on Assets

-64.25%

N/A

Return on Invested Capital

-75.32%

N/A

Free Cash Flow

-$21.53M

+19.9%

Operating Cash Flow

-$21.49M

+15.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRXPNRx Pharmaceuticals, Inc.
$4.35+1.87%
GANXGain Therapeutics, Inc.
$1.68-2.05%
TCRXTScan Therapeutics, Inc.
$0.92+0.84%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.76+0.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
BIYABaiya International Group
$5.05+0.22%
ADVBAdvanced Biomed
$8.37+0.66%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.45+0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.54-0.03%

Questions About ACET

What is the current price of Adicet Bio?

Adicet Bio is trading at $8.03 per share.

What is the 52-week range for Adicet Bio?

Over the past 52 weeks, Adicet Bio has traded between $6.01 and $17.44.

How much debt does Adicet Bio have?

As of the most recent reporting period, Adicet Bio reported total debt of $13.90M.

How much cash does Adicet Bio have on hand?

Adicet Bio reported $36.25M in cash and cash equivalents in its most recent financial results.

What is Adicet Bio’s dividend yield?

Adicet Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services